Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2015)
13 slides from Biotron's shareholder meeting presentation, Nov 24, 2015
Slide 1: Biotron Limited AGM
BIOTRON LIMITED (ASX:BIT) AGM 24 November, 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presenta,on may contain forward-‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec,ves of its management. These statements are statements tha
Slide 3: Biotron Snapshot
Biotron Snapshot • Leader in developing viroporin inhibitors for the treatment of viral infec,ons • Viroporin targets include influenza (M2), HIV-‐1 (Vpu), Hep C (p7), Dengue (M ), SARS (E), RSV (SH) and others • Crucial for viral pathogenesis • Rapid proprietary primary bacterial cell-‐based scree
Slide 4: Biotron's Core Technology & Pipeline
Biotron’s Core Technology & Pipeline Designed library of compounds to Compounds screened in target viroporins: proprietary assay set up for OTHER “HITS” IN LIBRARY include: each virus target e.g. HIV-‐1 IniJally >250 compounds designed and synthesised; library now ~350 Vpu; HCV p7; Influenza M2; Den
Slide 5: BIT225 - Proven Clinical Track Record
BIT225 -‐ Proven Clinical Track Record -‐ Over 200 pa,ents and healthy volunteers dosed with BIT225 to date -‐ Promising clinical efficacy against HIV-‐1 and HCV -‐ HCV GT1 (BIT225-‐005) – 100% receiving 400mg BID for 28 days in combina,on with 48 weeks IFN/RBV (per protocol) were virus-‐free a
Slide 6: BIT225 – Positioning Within HCV Landscape
BIT225 – PosiJoning Within HCV Landscape • Aim has been to generate data for posi,oning of BIT225 for partnerships • Focus has been on: • Defining genotype ac,vity in vitro and in vivo • Genera,ng pharmacokine,c (PK) data on BIT225 • Genera,ng suppor,ng toxicology and non-‐clinical data package • Ge
Slide 7: BIT225-008 Trial
BIT225-‐008 Trial • Preliminary data from HCV GT3 cohort: • Response to IFN/RBV was much higher than historical controls had indicated • Rates influenced by age, gender, liver damage, gene,cs, etc • High SVR12 rate in control arm means cannot show a BIT225 effect • BUT we have data demonstra,ng pan-
Slide 8: HIV-1 – Towards a Cure
HIV-‐1 – Towards a Cure • Infec,on rates in Australia are at 20 year high • Over 1.1 million people living with HIV-‐1 in the USA, with 1 in 6 unaware of diagnosis • US$11.9 bn sales in US, Europe and Japan in 2013; expected to grow to US$16.8 bn by 2020 • HIV-‐1 pa,ents need to stay on an,retrov
Slide 9: BIT225 Targets HIV-1 in Reservoir Cells
BIT225 Targets HIV-‐1 in Reservoir Cells • BIT225 inhibits assembly and budding of new virus • Phase 2a trial (BIT225-‐004) showed that BIT225 can reduce HIV-‐1 levels in macrophage cells in vivo, paralleling in vitro studies • Poten,al benefits on immune aging and HIV-‐associated demen,a • Poten
Slide 10: Unlocking Value in Compound Library
Unlocking Value in Compound Library • Renewed interest in targe,ng viral diseases including • Respiratory syncy,al virus (RSV) • Influenza (in par,cular drug resistant strains) • Hepa,,s B virus • Tropical diseases including Dengue • Ebola and MERS-‐CoV outbreaks have caused public health issues wor
Slide 11: Dengue Virus Program
Dengue Virus Program • 2.5 billion people (40% world popula,on) live in areas at risk of Dengue • ~100 million people infected yearly • A leading cause of illness and death in tropics and subtropics • Transmission is by mosquito; most preven,on programs target the vector • No approved Dengue-‐speci
Slide 12: Investment Proposition
Investment ProposiJon • HCV and HIV are high growth, mul,-‐billion dollar markets • Treatment gaps remain • BIT225 is a novel approach with demonstrated promising efficacy in Phase 2a/2 clinical trials • Represents a new class of direct-‐ac,ng HCV drugs • Poten,al to fill significant HCV treatment gap
Slide 13: Outlook for 2015/16
Outlook for 2015/16 • Complete BIT225-‐008 HCV trial currently in progress • SVR12 for G1 due 1Q16 • Inves,ga,onal New Drug applica,on (IND) • Finalise regulatory documenta,on containing an extensive data package • Partner for HCV combina,on studies • Progress protocol and regulatory documenta,on f